FindTrial
Sign In

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

BIOLOGICAL8 trials

Sponsors

CanSino Biologics Inc., Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China, NPO Petrovax

Conditions

COVID-19Covid19

Phase 1

Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults
CompletedNCT04313127
CanSino Biologics Inc.COVID-19
Start: 2020-03-16End: 2021-02-20Updated: 2021-08-04
Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada
NCT04398147
CanSino Biologics Inc.COVID-19
Start: 2020-08-01End: 2021-12-30Target: 696Updated: 2020-07-02
Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation
CompletedNCT04840992
CanSino Biologics Inc.COVID-19
Start: 2021-04-21End: 2022-08-09Updated: 2023-02-08

Phase 2

A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)
CompletedNCT04341389
Institute of Biotechnology, Academy of Military Medical Sciences, PLA of ChinaCOVID-19
Start: 2020-04-12End: 2020-12-31Updated: 2023-05-24
A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
CompletedNCT04566770
CanSino Biologics Inc.COVID-19
Start: 2020-09-24End: 2022-01-19Updated: 2022-10-31

Phase 3

Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above
CompletedNCT04526990
CanSino Biologics Inc.COVID-19
Start: 2020-09-15End: 2022-10-21Updated: 2023-06-15
Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19
CompletedNCT04540419
NPO PetrovaxCovid19
Start: 2020-09-11End: 2021-07-30Updated: 2024-04-23
A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents
TerminatedNCT05169008
CanSino Biologics Inc.COVID-19
Start: 2022-02-25End: 2023-01-13Updated: 2023-06-15

Related Papers

Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial
Vaccine2026-03-19
Clonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein
Frontiers in Immunology2024-04-027 citations
Vaccination with Adenovirus Type 5 Vector-Based COVID-19 Vaccine as the Primary Series in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Clinical Trial
Vaccines2024-03-116 citations
Safety and Immunogenicity of Homologous Recombinant Adenovirus Type 5-Vectored COVID-19 Vaccine Booster Dose in Healthy Adults Aged 18-60 Years: a Single-Center, Open-Label Trial.
2023-12-012 citations
Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19
Human Vaccines & Immunotherapeutics2023-07-102 citations
Environmental Impact Assessment for the Use of an Orally Aerosolized Adenovirus Type-5 Vector-Based COVID-19 Vaccine in Randomized Clinical Trials
The Journal of Infectious Diseases2023-05-181 citations
Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia
PLoS ONE2023-03-087 citations
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
2021-12-23172 citations
Safety and Immunogenicity of a Recombinant Adenovirus Type-5–Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial
Clinical Infectious Diseases2021-09-21102 citations
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19
Molecular Therapy2021-04-2357 citations
COVID-19 vaccines
Current Medicine Research and Practice2021-01-011 citations
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
2020-07-20893 citations
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
2020-05-221004 citations